Drug profile · INN
ruxolitinib
JAKAVI
- US status
- approved
- Patents linked
- 0
- News articles
- 3
Quick answer
ruxolitinib (JAKAVI) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Related news
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood disorders and GVHD patients.
Frequently asked questions
What is ruxolitinib?
ruxolitinib (JAKAVI) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ruxolitinib?
JAKAVI is a marketed brand name for ruxolitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ruxolitinib?
ruxolitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.